Accelerating Diagnostic Adoption: Gaining
Premise
Oncology is super complex, to say the least. HCPs couldn’t always determine whether a patient had residual disease after treatment until cancer became detectable through conventional imaging or clinical symptoms. With an ultrasensitive liquid biopsy platform for detecting minimal residual disease (MRD), treatment effectiveness, recurrence and monitoring could be improved if awareness could be increased and oncologist adoption was more widespread.
Precedent
An integrated approach including brand evolution, animation, product packaging, new reporting, social media and live events translated a highly technical scientific breakthrough into a compelling clinical and commercial value proposition. The “Seeing Care Forward” campaign communicated the value of detecting cancer earlier and more precisely, as well as how MRD data could enable life-changing decision-making.


















